Future vision for the quality assurance of oncology clinical trials
- PMID: 23508883
- PMCID: PMC3598226
- DOI: 10.3389/fonc.2013.00031
Future vision for the quality assurance of oncology clinical trials
Abstract
The National Cancer Institute clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based process improvements for clinical oncology patient care. The cooperative groups are undergoing a transformation process as we further integrate molecular biology into personalized patient care and move to incorporate international partners in clinical trials. To support this vision, data acquisition and data management informatics tools must become both nimble and robust to support transformational research at an enterprise level. Information, including imaging, pathology, molecular biology, radiation oncology, surgery, systemic therapy, and patient outcome data needs to be integrated into the clinical trial charter using adaptive clinical trial mechanisms for design of the trial. This information needs to be made available to investigators using digital processes for real-time data analysis. Future clinical trials will need to be designed and completed in a timely manner facilitated by nimble informatics processes for data management. This paper discusses both past experience and future vision for clinical trials as we move to develop data management and quality assurance processes to meet the needs of the modern trial.
Keywords: Clinical Trials Cooperative Group Program; National Cancer Institute; oncology clinical trials; quality assurance; radiation oncology.
Figures
References
-
- Abrams R. A., Winter K. A., Regine W. F., Safran H., Hoffman J. P., Lustig R., et al. (2012). Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704 – a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int. J. Radiat. Oncol. Biol. Phys. 82 809–816 - PMC - PubMed
-
- Chang D. T., Feigenberg S. J., Indelicato D. J., Morris C. G., Lightsey J., Grobmyer S. R., et al. (2007). Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selection. Int. J. Radiat. Oncol. Biol. Phys. 67 1043–1051 - PubMed
-
- Citron M. L., Berry D. A., Cirrincione C., Hudis C., Winer E. P., Gradishar W. J., et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21 1431–1439 - PubMed
-
- D’Angio G. J. (1980). Introduction: total body irradiation conference. Int. J. Radiat. Oncol. Biol. Phys. 6 744 - PubMed
-
- Dharmarajan K. V., Friedman D. L., FitzGerald T., McCarten K. M., Constine L. S., Kessel S. K., et al. (2012a). Radiation therapy quality assurance on AHOD0031: a report from the Quality Assurance Review Center (QARC) and the Children's Oncology Group. American Society for Radiation Oncology 54th Annual Meeting, Boston, MA. Int. J. Radiat. Oncol. Biol. Phys. 84 S162
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
